Introduction
============

There are several approaches to identifying low-penetrance candidate genes for breast cancer. In one approach, it is assumed that missense variants of genes for which truncating mutations are clearly pathogenic might also be deleterious. If the missense allele demonstrates high penetrance (i.e. like truncating mutations), then it will be relatively straightforward to establish the association when allele frequency is high. If the penetrance of the missense variant is low, however, then the association may be missed if only a small number of cancers is studied and the variant may falsely be classified as a neutral polymorphism. We are in the process of establishing a large database of breast cancer cases and ethnic-matched controls in order to evaluate the pathogenicity of the common founder alleles of the most important cancer susceptibility genes. Several deleterious founder alleles have been identified in *BRCA1*, but to date, no founder mutation in *BRCA2*has been identified \[[@B1]-[@B3]\]. There are a few common variant alleles in *BRCA2*in Poland; one of these (C5972T) changes the amino acid sequence of BRCA2 from threonine to methionine at codon 1915. It lies within the range of the BRC encoded by exon 11 that are thought to be involved in binding to RAD51 \[[@B4]\]. We sought to determine whether this common missense BRCA2 variant plays a role in breast cancer susceptibility.

Materials and methods
=====================

Study subjects
--------------

The study population included prospectively ascertained cases of invasive breast cancer diagnosed at 50 years of age or less at 18 treatment centers throughout Poland between 1997 and 2003. Invitation to participate was delivered during hospital stay or by mail. During the interview, the goals of the study were explained, informed consent was obtained, genetic counseling was offered, and a blood sample was taken for DNA analysis. A detailed family history of cancer was taken (first-, second-, and third-degree relatives included) and a risk factor questionnaire was completed. A total of 4,778 cases of early onset invasive breast cancer were identified at the 18 participating centers during the study period. Of these, 3,627 women (76%) accepted to participate and provided a blood sample for DNA analyses, 114 died, and 16 refused to participate. The medical record and pathology report were reviewed. In the end, we had DNA available for genotyping from 3,241 patients.

Controls
--------

Two control groups were combined. The first group consisted of 2,000 unselected neonates from ten hospitals throughout Poland born in 2003 and 2004. Samples of cord blood were forwarded to the study center in Szczecin. The second control group consisted of 1,000 adults from the region of Szczecin unselected for cancer family history, sex, or age. We genotyped 2,791 controls for the C5972T allele, 1,993 neonates and 798 adults. To ensure comparability of the control groups, C5729T allele frequencies were computed separately for the adult and neonatal control groups and compared. The study protocol was approved by the ethics committee of the Pomeranian Medical University.

Laboratory methods
------------------

All experiments were performed at the Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland.

### DNA isolation

DNA samples were obtained from peripheral blood of adults or from cord blood of neonates using the non-enzymatic rapid method as described previously \[[@B5]\].

### Analysis of the C5972T variant

The C5972T variant (Thr1915Met) was analyzed by restriction fragment length polymorphism PCR using b5972F (5\'-CTC TCT AGA TAA TGA TGA ATG ATG CA) and b5972R (5\'-CCA AAC TAA CAT CAC AAG GTG) primers. The forward primer introduces an artificial restriction site for the Mph1103I enzyme (Fermentas, St. Leon-Rot, Germany)

PCR products were digested in mutation positive cases. PCR products were separated in 3% agarose gel and visualized in ultraviolet light. For positive cases with RFLP-PCR (cleaved by Mph1103I), a DNA sample was sequenced to confirm the presence of the mutation. Additionally, 72 randomly selected samples negative with RFLP-PCR for the C5972T variant were sequenced. The results of RFLP-PCR and of direct DNA sequencing were 100% concordant.

DNA sequencing
--------------

A fragment of *BRCA2*exon 11 was amplified by PCR using b5972F/b5972R primers. The purified PCR products were sequenced directly with a BigDye Terminator v3.0 DNA Sequencing Kit (Perkin Elmer, Foster City, CA, USA) and the same reverse primer used previously for the amplification of exon 11 of the *BRCA2*gene. Products of sequencing reactions were separated and analysed on the ABI 377 DNA Sequencer (Perkin Elmer).

*BRCA1*testing
--------------

All breast cancer patients were tested as described previously \[[@B4]\] for three mutations (5382insC, C61G, 4153delA) representing 80% to 90% of all high-risk *BRCA1*changes in Poland.

Statistical analysis
--------------------

Statistical analysis included a comparison of the prevalence of the C5972T allele in cases and controls. Odds ratios (ORs) were generated from two-by-two tables and statistical significance was assessed with the chi-square test. *BRCA2*nucleotides were identified according to the GeneBank U43746 sequence.

Results
=======

The C5972T variant was detected in 8.3% of unselected breast cancer patients diagnosed at age 40 years or below, in 5.7% of cases diagnosed from age 41 to 50 years, and in 5.8% of Polish controls. The overall OR for breast cancer with a C5972T mutation was 1.1 (95% CI: 0.8--1.3); however, in women less than 40 years old the OR was 1.4 (95% CI: 1.0 -- 1.9) (Table [1](#T1){ref-type="table"}).

We found 13 C5972T homozygotes (11 patients and 2 controls). The OR associated with the homozygous state was 4.7 (95% CI: 1.1 to 21.4). Among 11 cases of breast cancer diagnosed in homozygotes, 10 were diagnosed between ages 40 and 50 years. The 11 homozygotes had predominantly intraductal (ductal carcinoma *in situ*(DCIS) with micro-invasion, 4 cases), ductal G3 (4 cases), lobular (2 cases), and ductal G2 (1 case) cancers. None of the first- or second-degree relatives of the homozygotes were diagnosed with breast or ovarian cancer.

We then explored the characteristics of the breast cancers that were identified in women with the *BRCA2*C5972T allele (Table [2](#T2){ref-type="table"}) and compared them with tumors in women without the predisposing allele (women with *BRCA1*mutations were excluded from all comparisons and women who received pre-operative chemotherapy were excluded from the histological comparisons). Women with the *BRCA2*variant were more likely to have bilateral cancer (5% versus 3%) or multifocal cancer (30% versus 23%) but these differences were not statistically significant. However, a significant effect was observed with intraductal cancer. Among the 5972C/T heterozygotes, 18 of 103 tumors were predominantly intraductal (17%), compared to 7% in 5972C/C breast cancer patients (OR = 2.82; p ≤ 0.0001; 95% CI: 1.6--4.8). A heterozygous *BRCA2*variant was present in 13% of the women with predominantly intraductal cancer. Compared to the population controls, the OR for intraductal cancer given a (heterozygous) form of *BRCA2*variant was 2.5 (p = 0.0005; 95% CI: 1.5--4.1). For women under 40 years old, the association was stronger (OR = 4.1; p = 0.006; 95% CI: 1.2--8.3).

Discussion
==========

The C5972T allele of the *BRCA2*gene appears to be over-represented in women with early onset breast cancer in Poland compared to controls. Although the effect was modest in the overall data set, it was stronger for women who had predominantly intraductal breast cancer and for women who were homozygous for the variant allele. Existing reports on the C5972T variant do not record any case of homozygote TT genotypes \[[@B6],[@B7]\]. It is of interest that the heterozygote state was associated with early onset breast cancer and the homozygote state with later onset cancer (above 40 years of age). To our knowledge, this has not been seen before and there is no compelling explanation; however, we believe that the sizes of these subgroups are small and require confirmation in other studies.

Our study population consisted of DCIS cases with a micro-invasive component only. To our knowledge, this is the first genetic association reported for intraductal cancer with micro-invasion. Our data set did not include cases of DCIS alone and we were unable to assess the effect of the *BRCA2*C5972T allele in women with predominantly invasive cancer and associated DCIS. These topics will be the focus of future studies. We did not see other pathological features that distinguished *BRCA2*-associated tumors from tumors in non-carriers. This situation is not different from that described for *BRCA2*carriers in general \[[@B8]-[@B10]\].

Several previous studies have shown that DCIS is a characteristic feature of cancers in *BRCA2*carriers \[[@B11]-[@B14]\]. In the case of *BRCA2*-associated breast cancers, it appears that loss of heterozygosity (LOH) occurs as a means of silencing the second allele. In one family with a germline *BRCA2*mutation, three cases of invasive breast cancer and one case of DCIS were observed \[[@B13]\]. LOH at the *BRCA2*locus was demonstrated in all four cases. The authors suggest that DCIS and LOH in the *BRCA2*locus may be common early steps in the development of invasive breast cancer in *BRCA2*carriers. The LOH data support the concept that *BRCA2*behaves as a tumor suppressor gene. In support of this hypothesis are our observations of a greater breast cancer risk in women with two inherited 5972T variants and a lower frequency of positive family history among 5972C/T heterozygotes.

In our study, we observed no association between the examined variant and increased family history. This may be explained by the modest association of the examined variant with breast cancer risk and probable recessive pattern of inheritance (the highest OR values were observed in homozygotes, all of them with negative breast cancer family history).

Actually, at least some of the 5972C/T heterozygotes may be compound heterozygotes, with the second allele being another *BRCA2*variant.

We now provide epidemiological and clinical evidence demonstrating the deleterious nature of the C5972T allele. To our knowledge, functional studies have not been performed on this variant. Few other deleterious missense variants in *BRCA2*have been identified.

The HH genotype of the non-conservative amino acid substitution polymorphism N372H in the *BRCA2*gene was reported to be associated with a 1.3-fold to 1.5-fold increase in the risk of both breast and ovarian cancer \[[@B15]-[@B18]\], but there have been negative studies as well \[[@B19],[@B20]\].

Our control group was drawn both from the newborns of 10 Polish cities and from the adult population in the region of Szczecin; however, the frequency of alleles was similar in the newborn (5.7%) and adult (5.8%) populations. There was no evidence that the genotype frequencies of the C5972T variants deviated from those expected from the Hardy-Weinberg equilibrium for the combined control group (p = 0.79) or for newborn and adult control groups (p = 0.59 and p = 0.73). There was no statistical difference in the C5972T allele frequencies in newborns recruited from the Szczecin metropolitan region compared to other Polish cities (data not shown). According to existing literature data, the frequency of the C5972T variant is similar in other populations such as North American, Austrian and Oceanian \[[@B6],[@B7]\].

Conclusion
==========

The heterozygosity of the *BRCA2*C5972T variant appears to be a neutral polymorphism in women above the age of 40 but may be deleterious prior to age 40. The risk associated with this allele was modest (OR = 1.4) in young women. Strong associations were not observed until cases were subclassified by their histological appearance or by homozygous state. It is important to confirm these observations in other populations. Large, well-controlled studies are needed to establish the full range of risks associated with other *BRCA2*alleles before they can definitely be identified as neutral. Identification of breast cancer susceptibility genes that are associated with modest penetrance requires very large association studies, unless the high-risk alleles are very common.
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DCIS = ductal carcinoma *in situ*; LOH = loss of heterozygosity; OR = odds ratio; RFLP-PCR = restriction fragment length polymorphism polymerase chain reaction.
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Figures and Tables
==================

###### 

Frequencies of the *BRCA2*C5972T variant allele in breast cancer patients and controls

  Variant                    Controls   Cases   Odds ratio   p-value   95% CI
  -------------------------- ---------- ------- ------------ --------- ---------------
  All subjects                                                         
   CC                        2,630      3,039   1.0                    
   CT                        159        191     1.0          0.74      \[0.8--1.3 \]
   TT                        2          11      4.8          0.02      \[1.1--21.4\]
   CT+TT                     161        202     1.1          0.45      \[0.9--1.3 \]
   Total                     2,791      3,241                          
                                                                       
  Cases under age 40 years                                             
   CC                        2,630      598     1.0                    
   CT                        159        51      1.4          0.04      \[1.0--2.0 \]
   TT                        2          1       2.2          0.46      \[0.2--23.7\]
   CT+TT                     161        52      1.4          0.03      \[1.0--1.9 \]
   Total                     2,791      650                            
                                                                       
  Cases 41+ years                                                      
   CC                        2,630      2,441   1.0                    
   CT                        159        140     0.9          0.68      \[0.8--1.2 \]
   TT                        2          10      5.4          0.02      \[1.2--24.6\]
  CT+TT                      161        150     1.0          0.97      \[0.8--1.3 \]
  Total                      2,791      2,591                          

CI, confidence interval.

###### 

Characteristics of breast cancers associated with 5972C/T or TT variants and wild-type *BRCA2*sequence

                               5972C/T or TT   Wild type   OR^a^   p-value   95% CI              
  ---------------------------- --------------- ----------- ------- --------- -------- ---------- ---------------
                               N               \%          N       \%                            
  Histology                                                                                      
   Medullary                   7               6           122     7         0.86     0.71       \[0.4--1.9\]
   Ductal                      41              36          607     35        1.04     0.83       \[0.7--1.5\]
   Tubular or tubulo-lobular   3               3           104     6         0.42     0.13       \[0.1--1.3\]
   Lobular                     22              19          364     21        0.90     0.70       \[0.5--1.5\]
   DCIS+micro-invasion         22              19          121     7         3.18     \<0.0001   \[1.9--5.2\]
   Other                       19              17          416     24        0.63     0.09       \[0.4--1.0\]
  Multifocal                   19              30          211     23        1.47     0.17       \[0.8--2.6\]
  Bilateral                    7               5           63      3         1.71     0.18       \[0.7--3.8\]
  ER+                          50              67          586     62        1.24     0.40       \[0.7--2.0\]
  Family history+^b^                                                                             
   All patients                32              21          569     26        0.72     0.14       \[0.5--1.2\]
   Diagnosed at \<40 years     4               10          97      24        0.36     0.06       \[0.1--1.1\]
                                                                                                 
                               0                           0                 0        p-value    95% CI
  Mean age (years)^c^          43.9                        44.4              0.5      0.34       \[-0.5--1.5\]
  Mean tumor size (cm)^c^      2.0                         2.1               0.1      0.41       \[-0.1--0.3\]

^a^Odds ratios (ORs) for individual variables represent the odds of being a mutation carrier for a woman with a particular characteristic, compared to all other women who did not have the characteristic. For histology the comparisons were made for one histological group to all other histologies. ^b^Family history+ indicates the occurrence of one or more breast or ovarian cancers among first and second degree relatives. ^c^For age and tumor size comparisons, p-values and confidence intervals refer to the difference of means. Data were missing from the following categories and these cases were excluded from the specific calculations: histology (909 cases), multi-focality (1,774 cases); bilaterality (744 cases), estrogen receptor status (1,746 cases), family history (756 cases), family history in group diagnosed \<40 (150 cases). Patients who received neo-adjuvant chemotherapy were excluded from all analyses with the exception of family history. 184 patients with *BRCA1* mutations were excluded from all analyses. ER+, estrogen receptor expression positive.
